Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial.

Name: Αlpha¹ Rigor Record — Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial.
Item: Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial.
Rating: 100
Author: Αlpha¹

Shitara K, Janjigian YY, Ajani J, Moehler M, Yao J, Wang X, Chhibber A, Pandya D, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Skoczylas T, Bragagnoli A, Liu T, Schenker M, Yañez P, Kowalyszyn R, Karamouzis M, Zander T, Feeney K, Elimova E, Doshi P, Li M, Lei M

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.75★ (Adequate), 0 critical, 3 high issues for “Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.75 / 5

Adequate — real issues to address

Observational Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
CitationsUnresolved reference−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced2 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Broken references and links1

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted post hoc exploratory biomarker analysis of a randomized phase 3 trial, with clear scientific premise, rigorous methods, and transparent reporting. The main weaknesses are minor reporting gaps: exact p-values are often given as thresholds, code sharing is not mentioned, and the specific IRB is not named. The integrity check flagged a low-severity internal contradiction in patient counts that should be clarified.

Both reviewers classified the study as observational (post hoc analysis of a randomized trial). The evaluation covered the full text, with verification components for citations, statistics, reproducibility, preregistration, and integrity. The statistics verification covered only 1 test due to limited reporting of test statistics; most p-values are threshold-only and could not be machine-verified.

6 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites prior studies on nivolumab-based regimens and molecular subtypes, and explicitly states that 'there has not been a comprehensive DNA or RNA analysis exploring the relationship of various pretreatment tumor characteristics with therapeutic outcomes in metastatic gastroesophageal adenocarcinoma.' The rationale linking the premise to the study objectives is logical, and the paper acknowledges limitations of prior work (e.g., limited studies on CIN/GS/EBV subtypes).

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior work on immune checkpoint blockade in gastroesophageal cancer and identifying a gap in comprehensive biomarker analyses.

Evidence

paraphrase[Introduction, paragraph 1-3]

“Nivolumab, a programmed death 1 (PD-1) inhibitor, plus chemotherapy, demonstrated superior OS compared with chemotherapy alone in previously untreated, nonhuman epidermal growth factor receptor 2 (HER2)-positive advanced gastric, gastroesophageal junction and esophageal adenocarcinoma in the CheckMate 649 study.”

direct quote[Introduction, paragraph 3]

“there has not been a comprehensive DNA or RNA analysis exploring the relationship of various pretreatment tumor characteristics with therapeutic outcomes in metastatic gastroesophageal adenocarcinoma.”